Abstract
Comprehensive genomic profiling (CGP) received approval in Japan in June 2019. The reported transition rate to matched targeted therapy based on CGP is ≤10% for pancreatic cancer (PC) and about 25% for biliary tract cancer (BTC). However, real-world data of CGP in hepatobiliary and pancreatic cancers remains limited. Herein, we investigated the success rate of CGP and the transition rate to matched targeted therapy based on CGP for hepatobiliary and pancreatic cancers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
